Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
Suicide After Deep Brain Stimulation of the Internal Globus Pallidus for Dystonia
Neurol 66:142-143, Foncke,E.M.J.,et al, 2006
Panic and Fear Induced by Deep Brain Stimulation
JNNP 77:410-412, Shapira,HN.A.,et al, 2006
Multiple Sclerosis - The Plaque and Its Pathogenesis
NEJM 354:942-955, Frohman,E.M.,et al, 2006
Hiccups Associated with Dopamine Agonists in Parkinson Disease
Neurol 66:774-775, Sharma,P.,et al, 2006
Benign Tremulous Parkinsonism
Arch Neurol 63:354-357,321, Josephs,K.A.,et al, 2006
What is the Risk of Developing Parkinsonism Following Neuroleptic Use?
Neurol 66:941-943, Noyes,K.,et al, 2006
Nonsteroidal Anti-Inflammatory Drugs and the Incidence of Parkinson Disease
Neurol 66:1097-1099, Hernan,M.A.,et al, 2006
Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006
Practice Parameter: Treatment of Parkinson Disease with Motor Fluctuations and Dyskinesia (An Evidence-Based Review)
Neurol 66:983-995, Pahwa,R.,et al, 2006
Practice Parameter: Diagnosis and Prognosis of New Onset Parkinson Disease (An Evidence-Based Review)
Neurol 66:968-975, Suchowersky,O.,et al, 2006
The Parkinsons Complex: Parkinsonism Is Just the Tip of the Iceberg
Ann Neurol 59:591-596, Langston,J.W., 2006
Role of COL4A1 in Small-Vessel Disease and Hemorrhagic Stroke
NEJM 354:1489-1496, Gould,D.B.,et al, 2006
Practice Parameter: Neuroprotective Strategies and Alternative Therapies for Parkinson Disease (An Evidence-Based Review)
Neurol 66:976-982, Suchowersky,O.,et al, 2006
Safety of Rasagiline in Elderly Patients with Parkinson Disease
Neurol 66:1427-1429, Goetz,C.G.,et al, 2006
Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases
JAMA 295:2483-2491,2535, Aoyama,H.,et al, 2006
Prospective Prevalence of Pathologic Gambling and Medication Association in Parkinson Disease
Neurol 66:1750-1752, Voon,V.,et al, 2006
Tetanus Vaccination and Risk of Multiple Sclerosis: A Systematic Review
Neurol 67:212-215, Hernn,M.A.,et al, 2006
Dopamine-Responsive Dystonia
eMedicine (Apr), Nikhar,N.K., 2006
Diffusion-Weighted Magnetic Resonance Imaging in the Syndrome of Acute Bilateral Basal Ganglia Lesions in Diabetic Uremia
Mov Disord 21:1267-1270, Kim, T.,et al, 2006
Phenotypic Spectrum Associated with Mutations of the Mitochondrial Polymerase y Gene
Brain 129:1674-1684, Horvath, R.,et al, 2006
The Role of Levodopa in the Management of Dementia With Lewy Bodies
JNNP 76:1200-1203, Moloy,S.,et al, 2005
The role of radiotracer imaging in Parkinson disease
Neurol 64:208-215, Ravina, B., et al, 2005
Amorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease
Neurol 64:392-393, Pot, C., et al, 2005
Immune-mediated rippling muscle disease
Neurol 64:364 367, Schulte-Mattler, W.J., et al, 2005
Bilateral Deep-Brain Stimulation of the Globus Pallidus in Primary Generalized Dystonia
NEJM 352:5 459-467, 498, Vidailhet, M., et al, 2005
Quantatative Assessment of Driving Performance in Parkinson's Disease
JNNP 76:176-180, 159, Wood, J.M., et al, 2005
Genetic Screening for a Single Common LRRK2 Mutation in Familial Parkinson's Disease
Lancet 365:410-412, Nichols, W.C., et al, 2005
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Arch Neurol 62:241-248, The PRESTO Study, 2005
The Pathophysiology of Watershed Infarction in Internal Carotid Artery Disease
Stroke 36:567-577, Momjian-Mayor, I. & Baron, J-C., 2005
Genetic Factors in Alzheimer's Disease
NEJM 352: 862-863, 884, Bird, T., 2005
"Levodopa Phobia": A New Iatrogenic Cause of Disability in Parkinson Disease
Neurol 64:923-924, Kurlan, R., 2005
The Serotonin Syndrome
NEMJ 352:1112-20, Boyer, E.W. & Shannon, M., 2005
Rasagiline as an Adjunct to Levodopa in Patients With Parkinsons Disease and Motor Fluctuations (LARGO, Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily, Study)
Lancet 365:947-954, 914, Rascol,O., et al, 2005
Excessive Daytime Sleepiness and Subsequent Development of Parkinson Disease
Neurol 65:1442-1446, Abbott,R.D.,et al, 2005
Levodopa Addiction in Idiopathic Parkinson Disease
Neurol 65:1508, Borek,L.L &Friedman,J.H., 2005
Modafinil for Daytime Somnolence in Parkinsons Disease: Double Blind, Placebo Controlled Parallel Trial
JNNP 76:1636-1639, Ondo,W.G.,et al, 2005
Two Patients With COMT Inhibitor-Induced Hepatic Dysfunction and UGT1A9 Genetic Polymorphism
Neurol 65:1820-1822, Martignoni,E.,et al, 2005
Diagnosis and Management of Dementia with Lewy Bodies
Neurol 65:1863-1872, McKeith,I.G.,et al, 2005
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Science and Ethics of Sham Surgery, A Survey of Parkinson Disease Clinical Researchers
Arch Neurol 62:1357-1360,1343, Kim,S.Y.H.,et al, 2005
Neurologic Spectrum of Chronic Liver Failure and Basal Ganglia T1 Hyperintensity on Magnetic Resonance Imaging, Probably Manganese Neurotoxicity
Arch Neurol 62:1385-1390, Klos,K.J.,et al, 2005
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Arch Neurol 62:1377-1381, Dodd,M.L.,et al, 2005
Neuropathology of Dementia in Parkinsons Disease: A Prospective, Community-Based Study
Ann Neurol 58:773-776,663, Aarsland,D.,et al, 2005
Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005
Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005
Campylobacter Gene Polymorphism as a Determinant of Clinical Features of Guillain-Barr Syndrome
Neurol 65:1376-1381,1350, Koga,M.,et al, 2005
Pure Midbrain Infarction
Neurol 64:1227-1232, Kim,J.S. & Kim,J., 2005
Pallidal vs Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease
Arch Neurol 62:554-560,533, Anderson,V.C.,et al, 2005
Simultaneous Carotid Endarterectomy and Coronary Artery Bypass Surgery in Canada
Neurol 64:1435-1437,1332, Hill,M.D.,et al, 2005